Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))

DRUG5 trials

Sponsors

CNBG-Virogin Biotech (Shanghai) Ltd.

Conditions

Advanced Intrahepatic CholangiocarcinomaAdvanced Malignant Solid TumorMetastatic Gastric CancerPrimary Hepatocellular CarcinomaPrimary Liver Cancer

Phase 1

Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors

CNBG-Virogin Biotech (Shanghai) Ltd.Advanced Malignant Solid Tumor

Start: 2021-04-14End: 2022-12-01Target: 18Updated: 2021-04-27

Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

RecruitingNCT04806464

CNBG-Virogin Biotech (Shanghai) Ltd.Primary Liver Cancer

Start: 2021-03-16End: 2024-12-31Target: 44Updated: 2024-09-19

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

RecruitingNCT06008925

CNBG-Virogin Biotech (Shanghai) Ltd.Metastatic Gastric Cancer

Start: 2022-11-17End: 2026-06-30Target: 43Updated: 2023-08-24

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Not yet recruitingNCT06124001

CNBG-Virogin Biotech (Shanghai) Ltd.Primary Hepatocellular Carcinoma

Start: 2023-11-30End: 2026-06-30Target: 36Updated: 2023-11-15

Phase 2

Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma

RecruitingNCT06746480

CNBG-Virogin Biotech (Shanghai) Ltd.Advanced Intrahepatic Cholangiocarcinoma

Start: 2022-03-19End: 2025-12-01Target: 33Updated: 2024-12-24

Related Papers

Oncolytic virus VG161 in combination with camrelizumab as second-line therapy in patients with advanced primary hepatocellular carcinoma: A phase Ib/IIa clinical study.

Journal of Clinical Oncology2025-05-28

Oncolytic virus VG161 in refractory hepatocellular carcinoma.

2025-03-1930 citations

Clinical outcomes from a phase I clinical trial of a novel oncolytic virus VG161 in patients with hepatocellular carcinoma (HCC) refractory after 2 prior lines of therapy including checkpoint inhibitors (CPI).

Journal of Clinical Oncology2024-06-0110 citations

Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases

Oncology Letters2024-04-032 citations

694 An open-label phase I dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of VG161 in patients with advanced primary liver cancer

Regular and Young Investigator Award Abstracts2022-11-012 citations